• Bedaquiline: Diarylquinoline Antibiotic for MDR-TB and Cance

  2026-05-30

  Bedaquiline stands apart as a diarylquinoline antibiotic with dual-action efficacy against multi-drug resistant tuberculosis and cancer stem cell populations. This article details advanced experimental workflows, protocol parameters, and troubleshooting guidance—empowering researchers to leverage Bedaquiline's multifaceted biology in both infectious disease and oncology settings.

• Leveraging (-)-Blebbistatin to Unravel Cytoskeletal-Cardiac

  2026-05-29

  This thought-leadership article explores how (-)-Blebbistatin, a selective non-muscle myosin II inhibitor, is enabling translational researchers to dissect actin-myosin interactions with newfound precision. By integrating mechanistic insight, strategic workflow guidance, and the latest discoveries in cardiac physiology—including the central role of HCN4 channels in temperature-driven heart rate responses—this piece charts an advanced path for cytoskeletal and cardiac research. It differentiates itself from standard product content by connecting cytoskeletal modulation to emerging cardiovascular paradigms, referencing both APExBIO’s product leadership and the latest peer-reviewed evidence.

• Phosphatase Inhibitor Cocktail (2 Tubes, 100X): Reliable Pho

  2026-05-29

  This article addresses persistent challenges in maintaining protein phosphorylation integrity during sample preparation, highlighting how the Phosphatase Inhibitor Cocktail (2 Tubes, 100X) (SKU K1015) offers evidence-based solutions. By examining real-world laboratory scenarios, it demonstrates the product’s impact on reproducibility, assay sensitivity, and workflow reliability for cell viability and signaling studies.

• Nicotine Signaling Accelerates Chronic Kidney Disease Progre

  2026-05-28

  This review synthesizes clinical and experimental evidence linking nicotine signaling to the progression of chronic kidney disease (CKD) in smokers. By highlighting the role of non-neuronal nicotinic acetylcholine receptors, oxidative stress, and pro-fibrotic pathways, the study provides a mechanistic basis for future therapeutic strategies targeting smoking-induced CKD.

• OfMYB1R114–OfSDIR1-like–OfCCD4 Module Regulates β-Ionone in

  2026-05-28

  This study reveals a regulatory network involving OfMYB1R114, OfSDIR1-like, and OfCCD4 that controls β-ionone synthesis in Osmanthus fragrans. The findings clarify the genetic and molecular mechanisms behind aroma compound production, with implications for both plant breeding and the fragrance industry.

• Sulfo-NHS-LC-Biotin: Parameters for Cell Surface Biotinylati

  2026-05-27

  Sulfo-NHS-LC-Biotin is a water-soluble, membrane-impermeable reagent optimized for covalent biotinylation of cell surface proteins via primary amines. It addresses the need for stable, irreversible protein labeling in fully aqueous systems, but is unsuitable for intracellular or reversible biotinylation applications.

• Magnetic CSNP-Exosome Hydrogel Restores Bladder Function in

  2026-05-27

  This study demonstrates that a magnetic chitosan nanoparticle-exosome hydrogel significantly improves bladder function in diabetic bladder dysfunction (DBD) by activating the FAK-p38 MAPK-GATA4 axis in adipose-derived mesenchymal stromal cells (ADSCs). The findings highlight the hydrogel's ability to promote vascular and neural repair, addressing longstanding challenges in ADSC-based therapies.

• DIDS (4,4'-Diisothiocyanostilbene-2,2'-disulfonic Acid) in A

  2026-05-26

  DIDS offers precise, mechanistically defined chloride channel inhibition, unlocking new experimental options in oncology, neuroprotection, and vascular research. This guide translates the latest mechanistic insights and protocol innovations into actionable workflows, troubleshooting tactics, and forward-looking strategies for maximizing the impact of DIDS in your lab.

• Dual Inhibition of FUBP1 and Topoisomerase I by SN-38 and Ca

  2026-05-26

  This study identifies 7-Ethyl-10-hydroxycamptothecin (SN-38), the active metabolite of irinotecan, and camptothecin as dual-action agents that inhibit both DNA topoisomerase I and the oncogenic transcriptional regulator FUBP1. The findings reveal a previously underappreciated mechanism for these compounds, informing advanced strategies for targeting proliferative and anti-apoptotic pathways in solid tumors.

• FH1 Small Molecule (B3700): Advancing Hepatocyte Maturation

  2026-05-25

  Explore how the FH1 small molecule enhances cultured hepatocyte function and iPS cell differentiation. This in-depth article unpacks FH1's mechanism, unique assay insights, and strategic value for advanced liver research.

• Toremifene in Breast Cancer: Two Decades of Endocrine Therap

  2026-05-25

  This review synthesizes 20 years of clinical evidence on toremifene, highlighting its role as a selective estrogen receptor modulator (SERM) in hormone-sensitive breast cancer. The findings emphasize biomarker-driven personalization, comparative efficacy with aromatase inhibitors, and the evolving therapeutic landscape in breast cancer management.

• SAR131675: Applied VEGFR-3 Inhibitor Workflows & Troubleshoo

  2026-05-24

  SAR131675 delivers unparalleled specificity as a VEGFR-3 inhibitor, empowering researchers to dissect lymphangiogenesis and tumor growth inhibition with protocol precision. This guide translates cutting-edge reference findings and recent workflow advances into actionable methods, optimization strategies, and troubleshooting for robust, reproducible results.

• Structural Dissection and Affinity Tuning of CD38 CAR Binder

  2026-05-23

  This study provides a structural and functional analysis of two distinct CD38-targeting CAR binders, uncovering how rational affinity tuning influences antigen engagement, enzymatic inhibition, and CAR-T cell selectivity. The findings offer a blueprint for engineering safer and more effective CAR-T therapies targeting hematologic malignancies.

• Pioglitazone: Orchestrating Immunometabolic Balance via PPAR

  2026-05-22

  Explore how Pioglitazone, a selective PPARγ agonist from APExBIO, advances translational research by modulating macrophage polarization and metabolic pathways. This thought-leadership article bridges mechanistic insight with strategic guidance, spotlighting recent breakthroughs in inflammation, diabetes, and neurodegenerative disease models.

• cgSHAPE-seq Maps RNA-Degrading Chimera Binding in SARS-CoV-2

  2026-05-22

  The referenced study introduces cgSHAPE-seq, a chemical-guided sequencing method that precisely locates small molecule binding sites within the SARS-CoV-2 5’ UTR, enabling the rational design of RNA-degrading chimeras. This approach advances RNA-targeted antiviral strategies and informs future applications in RNA manipulation and therapeutic development.

15660 records 1/1044 page Next 12345 下5页 Last page